Nothing Special   »   [go: up one dir, main page]

DK1530636T3 - Behandling af melanomer ved reduktion af clusterinniveauet - Google Patents

Behandling af melanomer ved reduktion af clusterinniveauet

Info

Publication number
DK1530636T3
DK1530636T3 DK03792074.1T DK03792074T DK1530636T3 DK 1530636 T3 DK1530636 T3 DK 1530636T3 DK 03792074 T DK03792074 T DK 03792074T DK 1530636 T3 DK1530636 T3 DK 1530636T3
Authority
DK
Denmark
Prior art keywords
clusterin
subject
bcl
treatment
effective amount
Prior art date
Application number
DK03792074.1T
Other languages
English (en)
Inventor
Burkhard Jansen
Martin E Gleave
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of DK1530636T3 publication Critical patent/DK1530636T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK03792074.1T 2002-08-21 2003-08-21 Behandling af melanomer ved reduktion af clusterinniveauet DK1530636T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US40815202P 2002-09-03 2002-09-03
US31974802P 2002-12-02 2002-12-02
US47238703P 2003-05-20 2003-05-20
PCT/CA2003/001276 WO2004018675A1 (en) 2002-08-21 2003-08-21 Treatment of melanoma by reduction in clusterin levels

Publications (1)

Publication Number Publication Date
DK1530636T3 true DK1530636T3 (da) 2010-11-29

Family

ID=31950766

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03792074.1T DK1530636T3 (da) 2002-08-21 2003-08-21 Behandling af melanomer ved reduktion af clusterinniveauet

Country Status (16)

Country Link
US (1) US7285541B2 (da)
EP (1) EP1530636B1 (da)
JP (1) JP4620585B2 (da)
KR (1) KR101052289B1 (da)
AT (1) ATE478142T1 (da)
AU (1) AU2003258425B2 (da)
CA (1) CA2494764C (da)
CY (1) CY1110936T1 (da)
DE (1) DE60333839D1 (da)
DK (1) DK1530636T3 (da)
IL (1) IL166657A (da)
NO (1) NO333254B1 (da)
NZ (1) NZ538288A (da)
PT (1) PT1530636E (da)
SI (1) SI1530636T1 (da)
WO (1) WO2004018675A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227190B1 (en) 1999-02-26 2010-10-28 Univ British Columbia Trpm-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1465995B1 (en) 2002-01-17 2008-07-30 The University of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
KR101238701B1 (ko) 2002-08-21 2013-03-05 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
DK1530636T3 (da) 2002-08-21 2010-11-29 Univ British Columbia Behandling af melanomer ved reduktion af clusterinniveauet
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US20050267060A1 (en) * 2004-03-19 2005-12-01 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
PL1814595T3 (pl) * 2004-11-23 2014-08-29 Univ British Columbia Leczenie raka za pomocą kombinacji czynnika zakłócającego ścieżkę sygnalizacyjną EGF oraz oligonukleotydu obniżającego poziom klusteryny
DK1937815T3 (da) 2005-09-13 2015-08-03 Nat Res Council Canada Fremgangsmåder og præparater til modulering af tumorcelleaktivitet
AU2006292293B2 (en) * 2005-09-19 2012-09-13 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
AU2008293138A1 (en) * 2007-08-28 2009-03-05 Auckland Uniservices Limited Cell marker of melanocyte cell lineage and uses thereof
AU2010324506B2 (en) 2009-11-24 2015-02-26 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP2685990A4 (en) 2011-03-15 2014-09-17 Univ British Columbia COMBINATION OF ANTI-CLUSTERIN OLIGONUCLEOTIDE AND HSP90 INHIBITOR FOR THE TREATMENT OF PROSTATE CANCER
WO2013063313A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
NZ626742A (en) 2012-02-22 2016-06-24 Alethia Biotherapeutics Inc Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
WO2014138338A1 (en) 2013-03-06 2014-09-12 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
CA2900533A1 (en) * 2013-03-14 2014-10-02 Oncogenex Technologies Inc. Anti-clusterin monotherapy for cancer treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6111094A (en) * 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US5646042A (en) 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
AU760549B2 (en) * 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6335194B1 (en) 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
AU3116800A (en) 1998-12-11 2000-06-26 Research Foundation Of The State University Of New York, The Compositions and methods for altering cell migration
HU227190B1 (en) * 1999-02-26 2010-10-28 Univ British Columbia Trpm-2 antisense therapy
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
MXPA02006167A (es) 1999-12-21 2004-02-26 Univ Yale Promocion de la angiogenesis con survivina.
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1465995B1 (en) 2002-01-17 2008-07-30 The University of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
KR101238701B1 (ko) * 2002-08-21 2013-03-05 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
DK1530636T3 (da) 2002-08-21 2010-11-29 Univ British Columbia Behandling af melanomer ved reduktion af clusterinniveauet
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US8061408B2 (en) 2009-10-13 2011-11-22 Varel Europe S.A.S. Casting method for matrix drill bits and reamers

Also Published As

Publication number Publication date
US7285541B2 (en) 2007-10-23
NZ538288A (en) 2008-04-30
CA2494764A1 (en) 2004-03-04
IL166657A0 (en) 2006-01-15
KR101052289B1 (ko) 2011-07-27
EP1530636B1 (en) 2010-08-18
AU2003258425A1 (en) 2004-03-11
KR20050058425A (ko) 2005-06-16
CA2494764C (en) 2013-04-23
JP4620585B2 (ja) 2011-01-26
ATE478142T1 (de) 2010-09-15
IL166657A (en) 2010-05-31
CY1110936T1 (el) 2015-06-10
JP2006502243A (ja) 2006-01-19
DE60333839D1 (de) 2010-09-30
PT1530636E (pt) 2010-11-17
NO20051426L (no) 2005-05-12
SI1530636T1 (sl) 2010-12-31
US20040082534A1 (en) 2004-04-29
WO2004018675A1 (en) 2004-03-04
NO333254B1 (no) 2013-04-22
EP1530636A1 (en) 2005-05-18
AU2003258425B2 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
CY1110936T1 (el) Θεραπεια μελανωματος με μειωση των επιπεδων της clusterin
Lee et al. Brazilin inhibits UVB-induced MMP-1/3 expressions and secretions by suppressing the NF-κB pathway in human dermal fibroblasts
WO2007085018A3 (en) Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
DK1196414T3 (da) Prolægemiddel af carbamathæmmer for IMPDH
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA200802329A1 (ru) Производные триазола ii
SE0301882D0 (sv) New use I
WO2001074376A3 (en) Cathepsin inhibitors in cancer treatment
UA89226C2 (en) Imidazole compounds
MXPA05012619A (es) Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
NO20033665L (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
AU2558300A (en) Substituted stilbene compounds with vascular damaging activity
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
Jia et al. (–)-Epigallocatechin-3-gallate protects human skin fibroblasts from ultraviolet a induced photoaging
MX339096B (es) Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades.
AU3934000A (en) Inhibitors of endothelin-1 synthesis
Lee et al. Radix clematidis extract inhibits UVB-induced MMP expression by suppressing the NF-κB pathway in human dermal fibroblasts
ATE294811T1 (de) Antisense-modulation von x-verbundenen inhibitoren der apoptosis-expression
Park et al. Effects of xanthium stramarium and psoralea corylifolia extracts combined with UVA1 irradiation on the cell proliferation and TGF-β1 expression of keloid fibroblasts
RS95304A (en) New combination fortreating airway disorders
SE0301885D0 (sv) New use IV
SI1003554T1 (en) Proton pump inhibitor in therapeutic combination with antibacterial substances
RS95204A (en) Combination for the treatment of airway disorders